Difference between revisions of "Aclarubicin (Aclacinon)"
m |
Warner-admin (talk | contribs) m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information") |
||
(3 intermediate revisions by 2 users not shown) | |||
Line 4: | Line 4: | ||
<br>Extravasation: [[irritant]] | <br>Extravasation: [[irritant]] | ||
− | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information. |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
Line 20: | Line 20: | ||
<references/> | <references/> | ||
− | [[Category: | + | [[Category:Drugs]] |
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
[[Category:Anthracyclines]] | [[Category:Anthracyclines]] | ||
− | [[Category:Topoisomerase inhibitors]] | + | [[Category:Topoisomerase I inhibitors]] |
+ | [[Category:Topoisomerase II inhibitors]] | ||
[[Category:Acute myeloid leukemia medications]] | [[Category:Acute myeloid leukemia medications]] | ||
[[Category:PMDA approved drugs]] | [[Category:PMDA approved drugs]] |
Latest revision as of 01:05, 29 June 2024
General information
Class/mechanism from NCI Drug Dictionary: An oligosaccharide anthracycline antineoplastic antibiotic isolated from the bacterium Streptomyces galilaeus. Aclarubicin intercalates into DNA and interacts with topoisomerases I and II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. Aclarubicin is antagonistic to other agents that inhibit topoisomerase II, such as etoposide, teniposide and amsacrine.
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
Diseases for which it is used
Patient drug information
No information available.
Also known as
- Code name: MA144-A1
- Generic names: aclacinomycin, aclacinomycin A, aclacinomycin A hydrochloride, aclacinomycin-A, aclarubicin hydrochloride
- Brand names: Aclacin, Aclacinomycine, Aclacinon, Aclaplastin, Jaclacin